Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | PER2 | O15055 | 2/20 | 0.37 |
| ▸ | CRY1 | Q16526 | 2/20 | 0.37 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | HTR7 | P34969 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | CCR5 | P51681 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707117 | 0.87 | GRM2 (0.39) | OPRM1HTR7KCNH2TACR1 | |
| SCHEMBL705075 | 0.82 | KCNH2 (0.36) | DRD2SLC6A4CCR3OPRM1TMEM97 | |
| SCHEMBL707961 | 0.82 | KCNH2 (0.40) | CCR3OPRM1TMEM97KCNH2CCR5 | |
| Trifluoroacetic Acid SCHEMBL706416 | 0.81 | DRD2 (0.39) | DRD2SLC6A4CCR3 | |
| SCHEMBL924021 | 0.81 | CNR2 (0.47) | DRD2SLC6A4HTR2AKCNH2 | |
| SCHEMBL707496 | 0.80 | KCNH2 (0.35) | DRD2SLC6A4CCR3OPRM1TMEM97 | |
| SCHEMBL705166 | 0.80 | DRD2 (0.45) | DRD2SLC6A4CCR3 | |
| SCHEMBL707111 | 0.79 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL706980 | 0.78 | KCNH2 (0.44) | KCNH2 | |
| SCHEMBL704124 | 0.77 | KCNH2 (0.38) | HTR2AHTR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | DRD2 3243/4885SLC6A4 4722/4885CCR3 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.